Oversight Committee Hearing on FDA Regulations and Crises Management

Regulations by 2FIRSTS.ai

Apr.09.2024

Oversight Committee Hearing on FDA Regulations and Crises Management

The House Oversight Committee will hold a hearing on FDA oversight with Director Robert Califf amid multiple crises.

According to the official website of the U.S. House of Representatives, the House Committee on Oversight and Reform will hold a hearing this week titled "Oversight of the Food and Drug Administration." Robert Califf, the Commissioner of the Food and Drug Administration, will testify and answer questions about the agency's regulation of tobacco and nicotine products.

The purpose of this hearing is to review the ongoing investigations by the oversight committee into the FDA's handling of various issues, including the infant formula crisis, food safety, drug shortages, facility inspections, cannabis regulation, tobacco and nicotine product regulation, as well as over-the-counter decongestants.

The oversight committee emphasized several crises that have occurred within the FDA's regulatory scope, pointing out that these events have had a negative impact on the lives and health of American citizens and families. Chairman of the oversight committee, James Comer, stated that they will be requesting the FDA Commissioner to explain the actions taken in response to the current crises, inspection measures to prevent nationwide crises in the future, and steps to ensure the primary protection of American consumers.

The hearing will be held on Thursday, April 11, 2024 at 1:00 PM Eastern Time, with witnesses including FDA Commissioner Dr. Robert Califf. The hearing will be open to the public and media, and will be live-streamed on https://oversight.house.gov/.

References:

[1] Oversight Committee to Hold Hearing with FDA Commissioner

Also Read:

[1] FDA Cracks down on Selling Flavored ZYN Products, 41 Physical Retailers Fined

[2] FDA Releases Series of Internal Memos on Tobacco Product Review Policies

[3] FDA Launches Searchable Tobacco Product Database for Retailers Compliance

#North America #United States #Traditional tobacco #Legislation #FDA

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philip Morris International Restructures to Drive Its Smoke-Free Transformation

Philip Morris International (PMI) announced a new organizational model effective January 1, 2026, creating two main business units — PMI International and PMI U.S. — to accelerate its smoke-free strategy. The restructuring replaces four regional segments with three: International Smoke-Free, International Combustibles, and U.S., enhancing agility, governance, and long-term growth in reduced-risk products.

Nov.05 by 2FIRSTS.ai

Russian State Duma considers regulations to address widespread use of e-cigarettes among youth

Russian Duma considers comprehensive regulations to address widespread e-cigarette use among youth, including potential sales bans and flavor restrictions.

Oct.20 by 2FIRSTS.ai

BAT Japan opens Glo flagship store in Tokyo's Ginza district, offering glo devices and tobacco sticks,

BAT Japan's flagship store in Tokyo's Ginza district opens, offering glo products, personalization services, and a VIP lounge.

Oct.20 by 2FIRSTS.ai

PMI’s Smoke-Free Playbook: What Jacek Olczak Really Told Wall Street

At the Morgan Stanley Global Consumer & Retail Conference on December 2, 2025, PMI CEO Jacek Olczak delivered a clear message: the company’s smoke-free shift is now its central strategy. From ZYN’s surge in the U.S. to IQOS’s global momentum and a changing regulatory tone, his remarks sounded less like an earnings update and more like a declaration of PMI’s smoke-free future.